| Shire announces name change | Posted on 02/10/2008 in Pharmaceutical Company Restructures Shire Limited has announced the results of its recent annual general meeting held last month, including a change in the company name to Shire plc.
The resolution to rename the global speciality biopharmaceutical company was passed by 331,323,817 to 31,609, with 159,462 votes being withheld.
Also at the meeting, Matthew Emmens, Angus Russell, Graham Hetherington, Barry Price, David Kappler, Jeffrey Leiden, Patrick Langlois, Kate Nealon, David Mott and Michael Rosenblatt were elected as directors of the firm.
Other motions passed that the meeting included the re-appointment of Deloitte & Touche as auditors of the firm and the authorisation of the audit, compliance and risk committee to determine their remuneration.
"Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority's Document Viewing Facility," Shire said.
It added its change in name would be effective as of the start of October 2008, following the registration of this change with Companies Registry in Jersey.
Last month, Shire announced the elections for its interim dividend in respect of the half-year period ending June 2008, having announced an interim dividend of 2.147 cents (0.012p) per ordinary share in July 2008.Other news stories from 02/10/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
